<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722212</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01473-50</org_study_id>
    <nct_id>NCT03722212</nct_id>
  </id_info>
  <brief_title>Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test</brief_title>
  <acronym>METAglut1</acronym>
  <official_title>Evaluation of METAglut1 Diagnostic Test Performances in Patients With a Clinical Suspicion of GLUT1 Deficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>METAFORA biosystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cemka-Eval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French National Authority for Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>METAFORA biosystems</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at validating the diagnostic performances of the METAglut1, a blood in vitro&#xD;
      diagnostic test, for the simple and early diagnosis of the GLUT1 deficiency syndrome&#xD;
      (GLUT1DS, or De Vivo disease).&#xD;
&#xD;
      The blood test will be carried out prospectively on patients presenting with a clinical&#xD;
      suspicion of GLUT1DS, blindly from the reference strategy, which consists in a lumbar&#xD;
      puncture for glycorrhachia measurement, completed by a molecular analysis.&#xD;
&#xD;
      The study will be conducted in more than 40 centers in France on up to 3,000 patients for 2&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GLUT1 Deficiency Syndrome (GLUT1-DS) is a debilitating, proteiform neurometabolic&#xD;
      disorder caused by an impairment in the glucose transporter GLUT1 at the cell surface.&#xD;
      Patients suffer from seizures, movement disorders and intellectual disabilities. A timely&#xD;
      diagnosis is of prime importance as this haploinsufficiency can be improved by the so-called&#xD;
      ketogenic diet.&#xD;
&#xD;
      By diagnosing GLUT1-DS early, based on symptoms associated with GLUT1-DS, healthcare&#xD;
      providers can prescribe the Keto diet therapy early in the disease progression, which could&#xD;
      prevent impairment of central nervous system function caused by the disease. Therefore, an&#xD;
      early diagnosis of GLUT1-DS for its treatment is crucial.&#xD;
&#xD;
      Currently, the disease is very difficult to diagnose correctly and in a timely manner. The&#xD;
      current diagnosis practice requires a lumbar puncture in order to determine if&#xD;
      hypoglycorrhachia occurs. The diagnosis result is then supported by the detection of a&#xD;
      heterozygous pathogenic variant in SLC2A1 gene. This diagnosis procedure is time consuming,&#xD;
      expensive, and requires a geneticist's data interpretation. Currently, ketogenic diet therapy&#xD;
      is the most efficient therapy for GLUT1-DS.&#xD;
&#xD;
      METAglut1 is a first-in-kind IVD device used to aid in the diagnosis of the GLUT1 Deficiency&#xD;
      Syndrome (GLUT1-DS) by quantifying the cell surface expression level of the glucose&#xD;
      transporter 1 (GLUT1) on circulating human red blood cells. The METAglut1 IVD is primarily&#xD;
      intended for use in pediatric patients older than 3 months, of both sexes, of any ethnic&#xD;
      origin. The METAglut1 IVD may also be used to aid in the diagnosis of GLUT1-DS in adults with&#xD;
      late onset symptoms.&#xD;
&#xD;
      The METAglut1 IVD is authorized for marketing in the European Union pursuant to the CE mark&#xD;
      and is currently being distributed in France.&#xD;
&#xD;
      The study aims to validate the diagnostic performances of METAglut1. It will last for 2&#xD;
      years, more than 40 centers will participate in the study across France. Up to 3,000 patients&#xD;
      with symptoms compatible with GLUT1-DS will be included prospectively; each of them will be&#xD;
      tested for METAglut1, in parallel and blindly of the reference strategy. The METAglut1 test&#xD;
      is performed by Laboratoire CERBA (Saint-Ouen l'Aumône, France). A retrospective cohort of&#xD;
      already diagnosed patients will also be analyzed to add more data. Concordance analysis with&#xD;
      the glycorrhachia, the first biochemical dosage involved in the reference strategy, will be&#xD;
      performed, and overall diagnostic performances of METAglut1 calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The METAglut1 test is performed on each patient, in parallel and blindly of the reference diagnostic strategy which is performed through the current practice.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The METAglut1 test is performed blindly of the reference strategy. METAglut1's result masking is maintained for the investigator on the one hand, and the glycorrhachia value masking is maintained for the centralized testing laboratory in charge of METAglut1 on the other hand.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance analysis of METAglut1 and glycorrhachia</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This analysis will be performed on patients with a diagnosis of certainty, either positive or negative, in the prospective cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, positive and negative predictive values of METAglut1</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>These analysis will be performed on patients with a diagnosis of certainty in the prospective cohort.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity, specificity of METAglut1</measure>
    <time_frame>Up to 6 moths</time_frame>
    <description>These analysis will be performed on patients with a diagnosis of certainty in the retrospective cohort.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to diagnosis</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The time between clinical suspicion of GLUT1-DS and diagnosis will be calculated and compared between different diagnostic strategies</description>
  </other_outcome>
  <other_outcome>
    <measure>Health technology assessment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Health technology assessment will be performed on patients included in the study</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Glut1 Deficiency Syndrome</condition>
  <condition>De Vivo Disease</condition>
  <condition>Seizures</condition>
  <condition>Movement Disorders</condition>
  <condition>Intellectual Disability</condition>
  <condition>Ataxia</condition>
  <arm_group>
    <arm_group_label>Patients for METAglut1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.&#xD;
Already diagnosed patients are included retrospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>METAglut1</intervention_name>
    <description>A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.</description>
    <arm_group_label>Patients for METAglut1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical suspicion of the GLUT1 Deficiency Syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sickle cell disease S/S&#xD;
&#xD;
          -  Abnormal imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny Mochel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Larrey- CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Léon</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier- APHP</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Pellegrin_ CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan_ CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mere enfant- CHU de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon_CHU Lyon</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Estaing- CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré- APHP</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord_CHU Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre _CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la mère et de l'enfant- CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone Enfant- APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac- CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère-Enfant_ CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital la Pitié-Salpêtrière-APHP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker- APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré- APHP</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau- APHP</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre- APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud de Rennes- CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord, CHU Saint-Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre- CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Tarbes - CH Bigorre</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan- CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants- CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Clocheville_ CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.metafora-biosystems.com</url>
    <description>METAglut1's project website</description>
  </link>
  <reference>
    <citation>Gras D, Cousin C, Kappeler C, Fung CW, Auvin S, Essid N, Chung BH, Da Costa L, Hainque E, Luton MP, Petit V, Vuillaumier-Barrot S, Boespflug-Tanguy O, Roze E, Mochel F. A simple blood test expedites the diagnosis of glucose transporter type 1 deficiency syndrome. Ann Neurol. 2017 Jul;82(1):133-138. doi: 10.1002/ana.24970.</citation>
    <PMID>28556183</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

